

William Patrick Fitzgibbons, M.D.
Cognitive Clinical Trials Research
1910 S Stapley Drive, Suite 120
Mesa, AZ 85204

CONTACT INFORMATION:

Site Selection and Information:
Bobbie Theodore, Alliance Director
Tel. (916) 939-6696
Fax (208) 575-3169
Email: clinicaltrials@alliancesites.com

AFFILIATIONS:

The Heritage at Sterling Ridge
1111 Sterling Ridge Drive
Omaha, NE 68144

West Omaha Family Physicians, P.C.
17030 Lakeside Hills Plaza, Suite 130
Omaha, NE 68130

Skyline Medical Center, PC
1908 N 203rd Street, Suite #2
Elkhorn, NE 68022

Methodist Physicians Clinic
350 W 23rd
Fremont, NE 68025

EDUCATION:

1978	M.D. Creighton University School of Medicine, Omaha, NE
1974	BA English Boston College, Boston, MA

RESIDENCY:

1978 - 1981 Family Medicine
San Bernardino County Medical Center, San Bernardino, CA

LICENSURE:

Nebraska MD License Number: 15830

HOSPITAL PRIVILEGES:

1985 – Present Methodist Hospital, Omaha, NE
1985 – Present Bergan Mercy Hospital, Omaha, NE
2004 – Present CHI Health Lakeside Hospital, Omaha, NE

PROFESSIONAL MEMBERSHIPS:

1981 – American Board of Family Medicine, Certified in Family Practice

PROFESSIONAL EXPERIENCE:

Principal Investigator, 2020 – Present
Cognitive Clinical Trials Research, Omaha, NE

Family Practice Physician, 1981 – Present
Skyline Medical Center, PC, Elkhorn, NE

Sub-Investigator, 2011 – 2013
Clinical Research Advantage, Inc., Elkhorn, NE

INVESTIGATOR EXPERIENCE:

Asthma • Cardiovascular Disease • Chronic Pain • COPD • Diabetes
Herpes Zoster-Associated Pain • Influenza • Migraine
Men’s Health • Osteoarthritis • Pain • Post Herpetic Neuralgia
Rheumatoid Arthritis • Shingles Treatment • Vaccines

ADDITIONAL INTEREST:

Allergy • Cardiology • Collection Studies • Dermatology • Devices • Endocrinology
Gastroenterology • Geriatrics • Immunology • Nutrition • Nephrology • Orthopedics • Pain
Oncology (Diagnostic studies and cancer pain) • Pulmonology • Rheumatology • Urology
Vaccines (COVID and other)

CLINICAL TRIAL EXPERIENCE:

Arthritis

Study to evaluate arthroplasty specimens in the Phase III XXX program for osteoarthritis of the knee and hip

A Phase III randomized, double-blind, multi-dose, placebo and nsaid-controlled study to evaluate the efficacy and safety of XXX in patients with pain due to osteoarthritis of the knee or hip

A Phase III randomized, double-blind, multi-dose, placebo-controlled study to evaluate the long-term safety and the efficacy of XXX in patients with pain due to osteoarthritis of the knee or hip

A Randomized, Double Blind, Parallel-Group Study Of Cardiovascular Safety In Osteoarthritis or Rheumatoid Arthritis Patients With or at High Risk for Cardiovascular Disease Comparing XXX With XXX and XXX

Asthma

A 26 week, randomized, active-controlled safety study of double-blind XXX in free combination with an inhaled corticosteroid versus an inhaled corticosteroid in adolescent and adult patients with persistent asthma

Cardiovascular

A Phase III multi-center, double-blind, randomized, placebo-controlled, parallel group evaluation of the efficacy, safety, and tolerability of XXX, in reducing the occurrence of major cardiovascular events in high risk subjects

A Phase III multi-center, double-blind, randomized, placebo-controlled, parallel group evaluation of the efficacy, safety, and tolerability of XXX, in reducing the occurrence of major cardiovascular events in high risk subjects

COPD

A Phase III, 1 2-week, Randomized, Double-Blind Placebo-Controlled Parallel-Group Study of XXX in Subjects with Chronic Obstructive Pulmonary Disease

Diabetes

A trial comparing the efficacy and safety of XXX and XXX in subjects with type 2 diabetes mellitus inadequately treated with basal XXX with or without oral antidiabetic drugs

A Phase IIIb, Randomized, Active Comparator, Open-label, Multicenter Study to Compare the Efficacy, Safety, and Tolerability of XXX to XXX and to XXX as Add-on Therapy to XXX in Patients with Type 2 Diabetes

CLINICAL TRIAL EXPERIENCE (*continued*):

Efficacy and safety of XXX versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only

A randomized, open-label, parallel-group real world pragmatic trial to assess the clinical and health outcomes of XXX compared to commercially available basal insulins for initiation of therapy in insulin naive patients with uncontrolled type 2 diabetes mellitus

Dose-finding of XXX administered subcutaneously once daily versus placebo and XXX in subjects with type 2 diabetes

A Randomized, Multicenter Study to Evaluate Cardiovascular Outcomes with XXX in Patients Treated with Standard of Care for Type 2 Diabetes

A randomized, double-blind, placebo-controlled, parallel-group, multiple dose study to evaluate the safety, pharmacokinetics and pharmacodynamic effects of XXX in obese adults with type-2 diabetes

Migraine

A Study of Two Doses of XXX (XXX and XXX) Compared to Placebo in the Acute Treatment of Migraine: A randomized, double-blind, placebo-controlled parallel group study

An Open-label Long term Safety Study of XXX (XXX and XXX) in the Acute Treatment of Migraine

Pain

A randomized, double-blind, multi-dose, placebo-controlled Phase III study to evaluate the efficacy and safety of XXX in patients with moderate to severe chronic low back pain

A Multicenter, Randomized, Double-Blind, Parallel-Group Comparative Study of XXX vs. XXX for the Prevention of Post-Herpetic Neuralgia and Treatment of Acute Herpes Zoster-Associated Pain

Other Indications

A Multicenter, Open-label, Efficacy and Safety Study of XXX for the Treatment of Hypogonadal Men

A Randomized Double-Blind Study Comparing XXX versus Placebo for the Treatment of Influenza in Low Risk Adults

A Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of XXX Nasal Spray in Adult Subjects with Symptoms of Common Cold

CLINICAL TRIAL EXPERIENCE (continued):

A Phase III, Observer-Blinded, Randomized, Active- Controlled (XXX), Multicenter Trial of the Safety and Immunogenicity of XXX in Adults 18 to 70 Years of Age

Vaccines

A Phase III, Randomized, Active-controlled, Observer-blinded Trial to Assess the Safety, Tolerability, and Immunogenicity of XXX in Healthy Participants ≥ 10 to < 26 Years of Age

A Multicenter Study Conducted to Evaluate the Performance of the XXX Flu A&B Assay at Point of Care Testing Sites

Evaluation of the Clinical Specificity of the Active Anthrax XXX Lateral Flow Immunoassay (LFI)

RATING SCALES EXPERTISE:

DDD
EQ-5D-5L
GDS
HIS-Q
II EF-5
I-PSS
Joint Pain Questionnaire

Knee Society
MIDAS
PDQ
PGA of OA
Survey of Autonomic Symptoms
Walking Index Joint Pain NRS
WOMAC